Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Autoimmune
Cancer
Cardiovascular
COVID-19
Health Topics
Infectious
Bladder Cancer
A. Menarini, Nucleix sign distribution agreement for bladder cancer test
By
LabPulse.com staff writers
A. Menarini Diagnostics and liquid biopsy firm Nucleix have signed a strategic partnership for the exclusive distribution of Nucleix's Bladder EpiCheck test.
September 9, 2024
Urine test halves use of invasive procedure to monitor bladder cancer
By
Nick Paul Taylor
A urine test can cut the number of cystoscopies necessary to follow up high-risk bladder cancer patients without increasing the risk of recurrence, a study has found.
April 11, 2024
Promis Diagnostics nabs FDA breakthrough device designation for bladder cancer test
By
LabPulse.com staff writers
The EarlyTect BCD test qualitatively detects an epigenetic biomarker, PENK methylation, associated with bladder cancer in the urine DNA of patients with hematuria.
April 28, 2023
Bladder cancer biomarker signature could identify likely responders to checkpoint inhibitors
By
Nick Paul Taylor
A diagnostic tool that identifies the patients most likely to respond to checkpoint inhibitors could enable physicians to determine the best treatment for each individual.
April 27, 2023
AnchorDx enrolling U.S. clinical trial for bladder cancer assay
By
LabPulse.com staff writers
The study, which will enroll more than 1,000 participants, aims to evaluate the noninvasive, qPCR assay which detects two DNA methylation biomarkers in urine specimens from patients suspected of having bladder cancer.
November 23, 2022
Nucleix announces CLIA certification, CAP accreditation for San Diego laboratory
By
LabPulse.com staff writers
Nucleix announced that it has received CLIA certification and CAP accreditation for its San Diego-based clinical laboratory.
October 19, 2022
Predicine to present posters on liquid biopsy tech at ESMO
By
LabPulse.com staff writers
Predicine's liquid biopsy portfolio includes assays that provide translational insights to aid in potential cancer therapeutic strategies.
September 8, 2022
Nanostics launches bladder cancer study
By
LabPulse.com staff writers
Its ClarityDX bladder test uses extracellular vesicle detection technology and machine-learning model analysis to identify the most potent disease predictors for the early detection of bladder cancer.
July 19, 2022
Nucleix expands EU label for bladder cancer test
By
LabPulse.com staff writers
Initially, the technology was indicated for the monitoring of tumor recurrence in conjunction with cystoscopy in patients previously diagnosed with bladder cancer.
June 21, 2022
Nonagen Bioscience secures CE Mark for bladder cancer test
By
LabPulse.com staff writers
The urine test detects 10 biomarkers associated with bladder cancer, the company said.
June 16, 2022
Paige, Janssen collaborating on AI-based bladder cancer test
By
LabPulse.com staff writers
Developed by Janssen, the test is a first-of-its-kind screening tool to predict the occurrence of actionable genomic alterations, Paige said.
June 14, 2022
Bio-Techne, Nonangen enter into agreement for Oncuria
By
LabPulse.com staff writers
The companies said they are targeting the last quarter of calendar year 2022 to make Oncuria available as a laboratory-developed test.
May 12, 2022
Page 1 of 2
Next Page
